VivoSeq
Oncology

Prostate Cancer

1.2K

Pipeline Programs↗

546

Active Trials↗

245

Companies Involved↗

Prostate Cancer is a highly competitive landscape with 1194 programs across 245 companies. The most active players are Bellicum Pharmaceuticals, FindCure Biosciences (ZhongShan) Co., Ltd., Taiho Oncology, Inc.. 63 therapies are approved with 151 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

90/100

Mech. Concentration

4/100

Completion Rate

74/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Bellicum Pharmaceuticals

4 programs

Phase 1F

FindCure Biosciences (ZhongShan) Co., Ltd.

3 programs

Phase 1Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

2 programs

Phase 1Inovio Pharmaceuticals logo

Inovio Pharmaceuticals

2 programs

Phase 1C

Cougar Biotechnology, Inc.

1 program

Phase 1O

Oncology Specialists, S.C.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical59

Mannitol

B. Braun Medical Inc.

Ifosfamide

Baxter Healthcare Corporation

Lidocaine Hydrochloride

Citius Pharmaceuticals, Inc.

Sildenafil

Viatris Specialty LLC

Gadolinium

OHSU Knight Cancer Institute

Phase 1278

Telmisartan

Boehringer Ingelheim

Crizotinib

Prism Pharmaceuticals

Desmopressin

Ferring

Tirzepatide

Eli Lilly

Tanespimycin

Bristol-Myers Squibb

Phase 2643

Simvastatin

Organon and Co

Aldesleukin

Iovance Biotherapeutics, Inc.

Pemetrexed Disodium

Gynecologic Oncology Group

Vinorelbine Tartrate

Gynecologic Oncology Group

Lapatinib Ditosylate

Novartis

Phase 3151

Cefazolin

Baxter Healthcare Corporation

Curcumin

Merck & Co.

Goserelin Acetate

AstraZeneca

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Capivasertib

AstraZeneca

Approved63

Olaparib

AstraZeneca

Darolutamide

Bayer

Tranexamic Acid

Amring

Bupropion

Glaxo Dba Glaxosmithkline

Ciprofloxacin

Bayer

Analysis

Modality Breakdown

88%

Small molecule

1,100 of 1,257 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody484%Vaccine353%Radiopharmaceutical353%Protein / enzyme11<1%Cell therapy11<1%Peptide7<1%Other10<1%

Small molecule leads; the ring shows all 1,257 classified programs, each share of the total. Modality classified for 99% of 1,400 pipeline programs.

Analysis

Trial Status

2,278

clinical trials

Completed1,167 · 51%
Terminated306 · 13%
Recruiting281 · 12%
Active, not recruiting192 · 8%
Unknown status140 · 6%
Withdrawn85 · 4%
Other107 · 5%

Clinical Trials

Trial Activity

2278 trials

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06216249·90 enrolled
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 3·NCT05352178·873 enrolled
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
Recruiting·MMayo Clinic·Phase 2·NCT06369610·110 enrolled
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
Recruiting·UUniversity of Chicago·Phase 2·NCT05790213·57 enrolled
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Recruiting·—·Phase 2·NCT06957691·60 enrolled
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Recruiting·MMayo Clinic·Phase 2·NCT06200103·236 enrolled
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Recruiting·UUniversity of Utah·Phase 2·NCT05168618·33 enrolled
PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)
Recruiting·TThe Netherlands Cancer Institute·Phase 4·NCT06875258·198 enrolled
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05873192·30 enrolled
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Recruiting·YYale University·Phase 2·NCT06111781·60 enrolled
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Recruiting·DDongkook Pharmaceutical Co., Ltd.·Phase 3·NCT06490328·154 enrolled
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
Recruiting·GGerman Oncology Center, Cyprus·Phase 2·NCT06772441·30 enrolled
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Recruiting·Amgen logoAmgen·Phase 1·NCT06613100·40 enrolled
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT06067841·140 enrolled
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
Recruiting·SSt Vincent's Hospital, Sydney·Phase 2·NCT06907641·50 enrolled
Page 1 of 152

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)